Arch Oncology
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT04445701) | Arch Oncology | 2020-11-30 |
| AO-176 in Multiple Solid Tumor Malignancies (NCT03834948) | Arch Oncology | 2019-02-04 |
Track Arch Oncology automatically
Every clearance here is in the API, with alerts when new ones post.